Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashFree Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tenax Therapeutics (TENX) Cash from Investing Activities (2016 - 2017)

Tenax Therapeutics' Cash from Investing Activities history spans 8 years, with the latest figure at $1.1 million for Q4 2017.

  • For Q4 2017, Cash from Investing Activities fell 90.93% year-over-year to $1.1 million; the TTM value through Dec 2017 reached $3.7 million, down 83.12%, while the annual FY2023 figure was $3000.0, 229.14% up from the prior year.
  • Cash from Investing Activities for Q4 2017 was $1.1 million at Tenax Therapeutics, up from $756129.0 in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $12.4 million in Q4 2016 and bottomed at -$34.6 million in Q3 2014.
  • The 5-year median for Cash from Investing Activities is $361486.5 (2013), against an average of -$1.2 million.
  • The largest annual shift saw Cash from Investing Activities crashed 104185.66% in 2014 before it skyrocketed 98.9% in 2015.
  • A 5-year view of Cash from Investing Activities shows it stood at -$35711.0 in 2013, then crashed by 12985.79% to -$4.7 million in 2014, then skyrocketed by 91.85% to -$380876.0 in 2015, then surged by 3350.11% to $12.4 million in 2016, then crashed by 90.93% to $1.1 million in 2017.
  • Per Business Quant, the three most recent readings for TENX's Cash from Investing Activities are $1.1 million (Q4 2017), $756129.0 (Q3 2017), and $800501.0 (Q2 2017).